


Non-small cell lung cancer Market Competition Analysis 2025: How Players Are Shaping Growth

The Business Research Company's Non-small cell lung cancer Global Market Report 2025 - Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, December 5, 2025

/EINPresswire.com/ -- [The Non-Small Cell Lung Cancer market](#) is dominated by a mix of global pharmaceutical leaders and emerging biotechnology firms. Companies are focusing on targeted therapies, immuno-oncology advancements, and precision medicine approaches to strengthen their market presence and improve patient outcomes. Understanding this evolving ecosystem is crucial for stakeholders aiming to identify growth opportunities, optimize treatment pipelines, and establish strong partnerships across the oncology value chain



The Business Research Company's Non-small cell lung cancer Global Market Report 2025 - Market Size, Trends, And Global Forecast 2025-2034"

The Business Research Company

Which Market Player Is Leading the non-small cell lung cancer Market?

According to our research, Merck & Co., Inc led global sales in 2024 with a 23% market share. The Tagrisso division of the company is completely involved in non-small cell lung cancer market, provides the adjuvant treatment after complete tumor resection in adults with stage IB-IIIa NSCLC with specific EGFR mutations. A recent Phase III trial showed a meaningful overall survival benefit with Tagrisso, especially when combined with chemotherapy. Imfinzi

(durvalumab) - Approved in 97 countries in the curative-intent setting of unresectable, Stage III NSCLC and in 63 countries for metastatic NSCLC. Approved in nine countries for resectable NSCLC. Enhertu(trastuzumab deruxtecan) - Approved in more than 50 countries for previously treated HER2- mutant metastatic NSCLC and in 60 countries for previously treated HER2-positive

advanced gastric ogastroesophageal junction adenocarcinoma

How Concentrated Is the non-small cell lung cancer Market?

The market is concentrated with the top 10 players accounting for 77% of total market revenue in 2024. This level of concentration reflects a few dominant pharmaceutical companies holding the majority of market share. Few large companies such as Merck & Co., Inc. and AstraZeneca are driven by the success of its immuno-oncology therapies. These companies maintain leadership through continuous innovation, global clinical trials, and diversified treatment pipelines. Meanwhile, firms such as Pfizer, Eli Lilly, Regeneron, Amgen, Novartis, and Takeda contribute to competition through targeted therapies and next-generation biologics. As precision medicine and combination therapies gain traction, strategic collaborations, licensing deals, and pipeline diversification are expected to further consolidate the dominance of [major players in the NSCLC market](#).

• Leading companies include:

- o Merck & Co., Inc. (23%)
- o AstraZeneca (23%)
- o Bristol-Myers Squibb Company (13%)
- o F. Hoffmann-La Roche AG (11%)
- o Pfizer Inc. (2%)
- o Eli Lilly and Company (2%)
- o Regeneron Pharmaceuticals Inc. (1%)
- o Amgen Inc. (1%)
- o Novartis AG (1%)
- o Takeda Pharmaceutical Company Limited (1%)

Request a free sample of the Non-Small Cell Lung Cancer Market report:

https://www.thebusinessresearchcompany.com/sample_request?id=13232&type=smp

Which Companies Are Leading Across Different Regions?

- North America: Johnson & Johnson, Pfizer Inc., AbbVie Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Amgen Inc., Viatris Inc., Regeneron Pharmaceuticals, Inc., Astellas Pharma Inc., Amneal Pharmaceuticals LLC, Clovis Oncology, Inc., Revolution Medicines, Inc., Apollomics Inc., Tempus Labs, Inc., AstraZeneca PLC, Novartis Pharmaceuticals Canada Inc. are some of the leading companies in this region.
- Asia Pacific: Hansoh Pharmaceutical Group Co., Ltd., Dizal (Jiangsu) Pharmaceutical Co., Ltd., Hutchison China MediTech Limited (HUTCHMED), Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Merck & Co., Inc., Akeso, Inc., Immuteq Limited, Eli Lilly and Company, Sanofi S.A., AbbVie Inc., Daiichi Sankyo Company, Limited, Johnson & Johnson, Amgen Inc., Yuhan Corporation, Samsung Medical Center, ONO Pharmaceutical Co., Ltd., Glenmark Pharmaceuticals Ltd, PT Etana Biotechnologies Indonesia, and Takeda Pharmaceutical Company Limited are some of the leading companies in this region.
- Western Europe: French-Speaking Pneumology Society (Société de Pneumologie de Langue

Française, SPLF), French Pneumo-Cancerology Group (Groupe Français de Pneumo-Cancérologie, GFPC), Lung Cancer Europe, German Cancer Society (Deutsche Krebsgesellschaft, DKG), German Respiratory Society (Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin, DGP), German Center for Lung Research (Deutsches Zentrum für Lungenforschung, DZL), German Cancer Consortium (Deutsches Consortium für Translationale Krebsforschung, DKTK), Italian Association of Thoracic Oncology (Associazione Italiana di Oncologia Toracica, AIOT), Italian Association of Medical Oncology (Associazione Italiana di Oncologia Medica, AIOM), Spanish Society of Medical Oncology (Sociedad Española de Oncología Médica, SEOM), Spanish Society of Pulmonology and Thoracic Surgery (Sociedad Española de Neumología y Cirugía Torácica, SEPAR), Spanish Association Against Cancer (Asociación Española Contra el Cáncer, AECC), British Thoracic Society (BTS), Roy Castle Lung Cancer Foundation, Asthma + Lung UK, National Lung Cancer Audit (NLCA), Oncogene-Driven Lung Cancer Patient Alliance (ODLC), British Oncology Pharmacy Association (BOPA), International Association for the Study of Lung Cancer (IASLC), Swedish Lung Cancer Association (Lungcancerföreningen), Swedish Cancer Society (Cancerfonden), Swedish Oncological Society (Svensk Onkologisk Förening, SOF), Norwegian Cancer Society (Kreftforeningen), Lung Foundation Netherlands (Longfonds), Dutch Association of Physicians for Lung Diseases and Tuberculosis (Nederlandse Vereniging van Artsen voor Longziekten en Tuberculose, NVALT), Dutch Cancer Society (Koninklijke Nederlandse Kankerbestrijding, KWF), Austrian Society for Hematology and Medical Oncology (Österreichische Gesellschaft für Hämatologie und Medizinische Onkologie, OeGHO), Austrian Society for Pneumology (Österreichische Gesellschaft für Pneumologie, ÖGP), Austrian Society for Thoracic Surgery (Österreichische Gesellschaft für Thoraxchirurgie, OGTC), Belgian Society of Medical Oncology (BSMO), Belgian Respiratory Society (BeRS), Danish Lung Cancer Group (Dansk Lungecancer Gruppe, DLCG), Portuguese Society of Pulmonology (Sociedade Portuguesa de Pneumologia, SPP), Cancer Society of Finland (Suomen Syöpäyhdistys), Finnish Lung Health Association (Filha), and Irish Lung Cancer Community (ILCC) are some of the leading companies in this region.

- Eastern Europe: Johnson & Johnson, Summit Therapeutics Inc., SOTIO Biotech AG, and BIOCAD JSC are some of the leading companies in this region.

- South America: Illumina, Inc., F. Hoffmann-La Roche Ltd, and QIAGEN N.V. are some of the leading companies in this region.

What Are the Major Competitive Trends in the Market?

- Developing bromodomain inhibitors is helping to block epigenetic readers.
- Example: TOLREMO Therapeutics AG (August 2025) assigns encouraging efficacy and safety in Phase 1 trials.
- These designations support accelerated development of TT125-802 as a differentiated therapy to address drug resistance in non-small cell lung cancer

Which Strategies Are Companies Adopting to Stay Ahead?

- Investing in targeted therapy and immunotherapy pipeline expansion to address unmet clinical needs and capture new patient segments.
- Collaborating with diagnostic and genomic companies to develop companion diagnostics and

precision medicine solutions.

- Enhancing real-world evidence (RWE) and clinical trial data generation to support regulatory approvals and market access.
- Expanding regional and global partnerships to increase accessibility of NSCLC treatments and strengthen market penetration.

Access the detailed Non-Small Cell Lung Cancer (NSCLC) Market report here:

<https://www.thebusinessresearchcompany.com/market-insights/non-small-cell-lung-cancer-nsclc-market-insights-2025>

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 17,500 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.

Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance.

Contact Us:

The Business Research Company

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email: info@tbrc.info

Follow Us On:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>"

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/872468633>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.